---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-22-009977"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2022-09-23T23:59:59+00:00"
generated_at: "2026-06-23T07:43:39.554490+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences shifts focus to cardiac/oncology, cuts workforce 40%, gets $65M loan from chairman

## Summary
- Reduce workforce by ~40% (to 66 employees); $200K severance charges in Q3 2022.
- Kevin Danahy named CEO (was CCO); Darrin Uecker becomes CTO; Robert Duggan appointed Executive Chairman.
- Robert Duggan provides $65M unsecured loan at 5% interest, due March 20, 2024.
- Company evaluating dermatology partnerships; plans investor day within 60 days.
- Shift from dermatology to cardiovascular, oncology, and other healthcare verticals.

## SEC filing metadata
- accession: 0001387131-22-009977
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2022-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.03, 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000138713122009977/0001387131-22-009977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000138713122009977/pulse-8k_092022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-22-009977
- JSON: https://secwatch.observer/filing/0001387131-22-009977.json
- Plain text: https://secwatch.observer/filing/0001387131-22-009977.txt

## Key facts
- Executive change
  Robert Duggan was elected as Executive Chairman at PULSE BIOSCIENCES, INC..
  - Action: elected
  - Role: Executive Chairman
  source text: Effective September 20, 2022, Mr. Duggan, who currently serves as a director and chairman of the Company’s Board, was elected Executive Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000138713122009977/0001387131-22-009977-index.htm
- Executive change
  Kevin Danahy was appointed as Chief Executive Officer at PULSE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Effective September 20, 2022, the board of directors (the “Board”) of the Company appointed Kevin Danahy to serve as Chief Executive Officer of the Company and Darrin Uecker to serve as Chief Technology Officer of the Company. Mr. Danahy previously served as the Company’s Chief Commercial Officer and Mr. Uecker previously served as the Company’s Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000138713122009977/0001387131-22-009977-index.htm
- Executive change
  Darrin Uecker was appointed as Chief Technology Officer at PULSE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Chief Technology Officer
  source text: Effective September 20, 2022, the board of directors (the “Board”) of the Company appointed Kevin Danahy to serve as Chief Executive Officer of the Company and Darrin Uecker to serve as Chief Technology Officer of the Company. Mr. Danahy previously served as the Company’s Chief Commercial Officer and Mr. Uecker previously served as the Company’s Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000138713122009977/0001387131-22-009977-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.